HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing?

Abstract
Aspirin plays a pivotal role in the management of patients with Coronary Artery Disease (CAD) with well-recognised benefits of reducing recurrent myocardial infarction and minimising the risk of stent thrombosis for those undergoing Percutaneous Coronary Intervention (PCI). Dual antiplatelet therapy is mandated for patients undergoing PCI and typically consists of aspirin and a P2Y12 receptor antagonist. Aspirin hypersensitivity poses a significant clinical dilemma, as the safety and efficacy of oral antiplatelet combinations that exclude aspirin have not been validated. Although, genuine hypersensitivity to aspirin is encountered infrequently, it can be challenging when managing patients with concomitant CAD given the paucity of safe and effective alternatives. Aspirin desensitization is a potential and safe option but may not always be practical. This review aims to highlight the challenges of aspirin hypersensitivity in patients undergoing PCI and propose a treatment algorithm to address this issue in clinical practice.
AuthorsGeorge Kassimis, Tushar Raina, Dimitrios Alexopoulos
JournalCurrent vascular pharmacology (Curr Vasc Pharmacol) Vol. 17 Issue 4 Pg. 326-331 ( 2019) ISSN: 1875-6212 [Electronic] United Arab Emirates
PMID29866010 (Publication Type: Journal Article, Review)
CopyrightCopyright© Bentham Science Publishers; For any queries, please email at [email protected].
Chemical References
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Aspirin
Topics
  • Algorithms
  • Animals
  • Aspirin (adverse effects)
  • Clinical Decision-Making
  • Coronary Artery Disease (therapy)
  • Decision Support Techniques
  • Desensitization, Immunologic (adverse effects)
  • Drug Hypersensitivity (diagnosis, etiology, immunology, prevention & control)
  • Drug Therapy, Combination
  • Humans
  • Percutaneous Coronary Intervention (adverse effects)
  • Platelet Aggregation Inhibitors (adverse effects)
  • Purinergic P2Y Receptor Antagonists (adverse effects, therapeutic use)
  • Risk Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: